Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of RP-6306 with
FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose
(MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess
preliminary anti-tumor activity.